Zatuximab Biosimilar – Anti-HER1 mAb – Research Grade

Introduction

Zatuximab Biosimilar, also known as Anti-HER1 mAb, is a monoclonal antibody that targets the human epidermal growth factor receptor 1 (HER1). This biosimilar is a research grade medication that has shown promising results in pre-clinical studies and is currently being evaluated for its potential therapeutic applications. In this article, we will explore the structure, activity, and potential applications of Zatuximab Biosimilar in detail.

Structure of Zatuximab Biosimilar

Zatuximab Biosimilar is a recombinant humanized monoclonal antibody that is produced using genetic engineering techniques. It is composed of two identical heavy chains and two identical light chains, each consisting of variable and constant regions. The variable regions of the antibody are responsible for binding to the HER1 receptor, while the constant regions provide stability to the molecule.

The antibody has a molecular weight of approximately 150 kDa and is composed of 1,340 amino acids. It belongs to the IgG1 subclass, which allows it to effectively activate the immune system and initiate an immune response against HER1-expressing cells.

Activity of Zatuximab Biosimilar

Zatuximab Biosimilar specifically targets the HER1 receptor, which is overexpressed in various types of cancer, including breast, lung, and colon cancer. By binding to HER1, the antibody blocks the receptor’s signaling pathway, which is responsible for promoting cell growth and survival. This inhibition of HER1 signaling can lead to the inhibition of tumor growth and the induction of cancer cell death.

Furthermore, Zatuximab Biosimilar has also been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms involve the activation of the immune system to target and kill cancer cells, providing an additional mechanism of action for the antibody.

Potential Applications of Zatuximab Biosimilar

Based on its activity, Zatuximab Biosimilar has potential applications in the treatment of various types of cancer. Pre-clinical studies have shown promising results in breast, lung, and colon cancer models, demonstrating the antibody’s ability to inhibit tumor growth and induce cancer cell death.

In addition, Zatuximab Biosimilar has also shown potential in combination therapy with other anti- cancer agents. Studies have shown that combining the antibody with chemotherapy or other targeted therapies can enhance its anti-tumor effects and improve treatment outcomes.

Moreover, Zatuximab Biosimilar has also been evaluated for its potential in treating HER1-expressing autoimmune diseases, such as psoriasis and rheumatoid arthritis. By targeting the HER1 receptor, the antibody can potentially suppress the overactive immune response and provide relief to patients suffering from these conditions.

Conclusion

Zatuximab Biosimilar, also known as Anti-HER1 mAb, is a promising research grade medication that specifically targets the HER1 receptor. Its unique structure and activity make it a potential therapeutic option for various types of cancer and autoimmune diseases. Further clinical studies are needed to fully evaluate the efficacy and safety of this biosimilar, but early results are promising, and it has the potential to become a valuable addition to the arsenal of anti- cancer therapies.

Keywords: Zatuximab Biosimilar, Anti-HER1 mAb, monoclonal antibody, HER1 receptor, cancer, autoimmune diseases, combination therapy.

ProteoGenix catalogue number PX-TA1921. For research use only.

Target: Zatuximab Biosimilar – Anti-HER1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet